Poland· PL-100485503
Columvi
A glofitamab product containing glofitamabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glofitamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX28 (glofitamab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Glofitamab · ATC L01FX28
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Glofitamabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01FX28
- ATC class
- Glofitamab
- Defined daily dose
- 1.43 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613326068468
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glofitamab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumColumvi 10 mgRoche Registration
- CzechiaCOLUMVIRoche Registration GmbH, Grenzach-Wyhlen
- FinlandColumviRoche Registration GmbH
- IrelandColumvi 10 mg concentrate for solution for infusionRoche Registration GmbH
- IcelandColumviRoche Registration GmbH*
- NorwayColumviRoche Registration GmbH
- SwedenColumvi 10 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- United StatesColumviGenentech, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Columvi
- Liechtenstein · Columvi
- Norway · Columvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/46704c1a-8b08-4030-9bb9-9274e388a92e GET /v1/drugs/46704c1a-8b08-4030-9bb9-9274e388a92e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg",
"packaging": "07613326068468 ¦ Rpz ¦ EU/1/23/1742/002 ¦ 150701\n1 fiol. 10 ml",
"substance": "Glofitamabum 1 mg/ml",
"common_name": "Glofitamabum",
"pl_product_id": "100485503",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about glofitamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.